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tope monoclonal antibodies (3-B-3, 2-B-6 and 1-B-5) following 
deglycosylation. 
Results: In monolayer culture, GAG synthesis of chondrocytes 
from normal cartilage increased significantly compared to unstim- 
ulated controls. This was blocked in the presence of antibodies 
to ~5 integrin, or ~VI~5 integrin, or CD47. Electrophoretic pat- 
terns of PGs following mechanical stimulation showed that newly- 
synthesized aggrecan was not fragmented or degraded, but the 
concentration of chondroitin-4-sulfate isomers with a large molec- 
ular weight was enhanced. Chondrocytes from OA grade III car- 
tilage synthesized significantly less GAG than other grades of 
chondrocytes. OA grade III chondrocytes howed a decrease in 
the synthesis of large molecular weight aggrecan core protein. 
The apparent intensity of the large molecular weight 350 KDa 
band increased following mechanical stimulation of OA grade I 
and II chondrocytes, in the presence of anti-~5 integrin antibody. 
MS through compression of OA chondrocytes in 3-D alginate cul- 
ture (disk formation) resulted in a decrease in GAG synthesis. 
This decrease was seen after cyclical pressurization of 30% at 
0.33Hz and 0.1Hz. This decrease was blocked by the presence 
of either anti-I~l or anti-~Vl~5 integrin antibodies. 
Conclusions: Transmembrane integrins ~5, ~VI~5 and CD47 are 
involved in the signal-transduction processes that lead to in- 
creased intact PG production by normal human articular chon- 
drocytes following mechanical stimulation. The results also sug- 
gests altered signal transduction in articular chondrocytes in OA 
following MS, and ~5, I~1 and ~VI~5 integrins may be involved in 
the altered mechano-transduction in chondrocytes from OA carti- 
lage. 
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Genetic factors cannot fully explain osteoarthritis. We hypothe- 
size that epigenetic hanges (heritable modifications of gene ex- 
pression that do not involve mutations in DNA sequence) play a 
major role in OA pathology. Since in somatic cells non-expressed 
genes are thought o be silenced by DNA methylation of cytosines 
of CpG dinucleotides, we examined the DNA methylation status 
of four genes that are silenced in normal articular chondrocytes, 
but expressed by degradative OA chondrocytes, namely MMP- 
3, -9, -13 and ADAM-TS4. We hypothesized that that abnormal 
gene expression in OA is the result of de-methylation, leading 
to 'unsilencing' and gene expression. Cartilage was harvested 
from the femoral heads of 16 OA and 10 femoral neck fracture 
(#NOF) patients; the latter suffered from osteoporosis and served 
as controls. The cartilage was milled in a freezer mill, DNA was 
extracted, digested with appropriate methylation-sensitive restric- 
tion enzymes, followed by PCR amplification. These enzymes do 
not cut at their specific cleavage sites if the CpGs are methylated 
and thus PCR bands indicate methylated CpGs, while absence 
of methylation results in absence of a PCR band. This method 
permits determining the methylation status of specific CpG sites. 
Immunocytochemistry showed absence of enzyme expression in 
control samples, whereas all clonal chondrocytes from advanced- 
stage OA cartilage were immunopositive. In control patients 80% 
of CpGs were methylated, but only 52% in degradative chondro- 
cytes of OA patients (p<0.001). For individual enzymes, the in- 
creases in de-methylation were as follows: for MMP-13 from 4 to 
20%; for MMP-3 from 30 to 57%; for MMP-9 from 47 to 81% and 
for ADAM-TS4 from 0 to 48%. Not all available CpG sites were 
equally sensitive to demethylation. Some sites remained uni- 
formly methylated in both OA and control samples, others were 
non-methylated even in the control samples. However, there was 
at least one crucial site for each degradative nzyme that exhib- 
ited the highest and statistically significant change in methylation 
status. These sites were at -110bp for MMP-13; -36 for MMP-9; 
-635 for MMP-3 and -753 for ADAM-TS4. There was no correla- 
tion between the percentage demethylation and the patient's age 
and no gender difference. 
Conclusions: The demonstrated association between abnormal 
gene expression of the MMPs and ADAM-TS4 and promoter 
DNA demethylation represents an epigenetic dysregulation that 
is clonally inherited by daughter cells. At present only an associ- 
ation between gene expression and methylation status has been 
shown and further studies are needed to confirm a causal re- 
lationship. However, it seems likely that loss of DNA methylation 
plays an important role in the pathogenesis of OA and future ther- 
apies might be directed at influencing the methylation status. 
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Background: We have previously linkage mapped an OA sus- 
ceptibility locus to chromosome 6. This linkage was restricted to 
females concordant for hip OA ascertained by the need for hip re- 
placement surgery. The linkage encompassed the COL9A1 gene, 
which codes for the ~1 polypeptide chain of type IX collagen. This 
collagen has an essential role in maintaining the structural in- 
tegrity of cartilage. We therefore considered COL9A1 a strong 
candidate. However, an analysis of the COL9A1 exons failed to 
reveal any variants associated with OA. F&ssler and colleagues 
have reported on a mouse col9al knockout hat develops an OA 
phenotype. Our failure to detect any associated coding variants 
in COL9A1 combined with the mouse data prompted us to specu- 
late that variation in cis regulatory elements of COL9A1 that influ- 
ence its expression may constitute the OA susceptibility that we 
have mapped to chromosome 6. To test for the existence of such 
polymorphism we measured the allelic expression of COL9A1 us- 
ing RNA extracted from the articular cartilage chondrocytes of OA 
patients. This revealed that over 50% of patients demonstrated 
differential allelic expression (DAE) of COL9A1 in their chondro- 
cytes. 
Aim of study: Having established that polymorphism in regula- 
tory elements of COL9A1 exist we set out to test non-coding re- 
gions of the gene, and its flanking sequences, for association to 
OA 
Methods: Thirty-two SNPs and 19 polymorphic microsatellite 
markers from within a 411 kb genomic interval that encompasses 
COL9A1 were genotyped in a cohort of female cases with hip OA 
and age-matched female controls. Alleles, genotypes and haplo- 
types of the polymorphisms were then tested for association by 
chi-square analysis. 
Results: An association was observed to a block of SNPs in a 
40kb interval extending from the 3'UTR of COL9A1 to its down- 
stream flanking region. These variants are in linkage disequilib- 
rium with pair-wise D' values > 0.8, implying that they are mark- 
ing the same association. One of the SNPs affects a canonical 
polyadenylation signal sequence within the 3' UTR of COL9A1. 
This gene contains two canonical polyadenylation signals, with 
the sequence AATAAA. It is the proximal (relative to the stop 
